DNA RNA and Cells

11 Apr 2022 BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
11 Apr 2022 Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
11 Apr 2022 PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022
11 Apr 2022 Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers
11 Apr 2022 CytoImmune Presents New Preclinical Data Demonstrating Potential of its Novel, Off-the-Shelf Natural Killer Cell-Based Therapies for the Treatment of Hematologic and Solid Tumor Cancers at AACR
11 Apr 2022 Seneca Therapeutics, Inc. Presents Promising New Preclinical Data Combining its Lead Oncolytic Immunotherapeutic SVV-001 in Combination with Checkpoint Inhibitors at the 2022 Annual AACR Meeting
11 Apr 2022 MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy
10 Apr 2022 Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
10 Apr 2022 Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
10 Apr 2022 Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting
09 Apr 2022 Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK™ Cell Engagers at the 2022 AACR Annual Meeting
09 Apr 2022 Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT 179, a HER2-targeted Allogeneic CAR-NK Cell Therapy
09 Apr 2022 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
08 Apr 2022 T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting
08 Apr 2022 Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements
07 Apr 2022 Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US
07 Apr 2022 Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
05 Apr 2022 AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in ETESIAN Phase IIb trial
04 Apr 2022 Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
02 Apr 2022 Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
01 Apr 2022 Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
01 Apr 2022 Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
01 Apr 2022 JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
01 Apr 2022 TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
30 Mar 2022 Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top